Resources
News
The FUS Foundation highlights RebrAIn’s advances and validates its Board
Recently, the Focused Ultrasound Foundation highlighted RebrAIn's success in obtaining its second FDA 510(k) approval - which extends the capabilities of its OptimMRI software to include new machine learning models for lesioning treatment of Essential Tremor, thereby...
RebrAIn Hosts Inaugural Medical Advisory Board Meeting (MAB)
RebrAIn recently held the inaugural meeting of its Medical Advisory Board (MAB), marking a significant milestone in the company’s ongoing mission to deliver transformative AI-powered tools to neurosurgeons. The meeting also underscored RebrAIn's pivotal role in...
RebrAIn completes enrollment ahead of schedule for PARKEO2 clinical trial
RebrAIn is pleased to announce the early completion of enrollment for the second phase of the PARKEO2 clinical trial, a pioneering study aimed at improving surgical treatments for Parkinson’s disease. Sponsored by the Bordeaux University Hospital (CHU de Bordeaux) and...
RebrAIn Co-Founders to Present Innovative VIM Targeting Techniques at WSSFN Biennial Meeting
RebrAIn is excited to announce that its co-founders, Prof. Emmanuel Cuny, MD, and Prof. Nejib Zemzemi, PhD, will be presenting groundbreaking research on VIM targeting techniques at the upcoming World Society for Stereotactic and Functional Neurosurgery (WSSFN)...
RebrAIn Achieves Second FDA 510(k) Clearance, Advancing AI-Powered Neurosurgical Targeting
RebrAIn is proud to announce its second FDA 510(k) clearance for the OptimMRI software, marking another significant milestone in our mission to revolutionize neurosurgical targeting through cutting-edge AI technology. This clearance expands our capabilities to assist...
MedTech Strategist Features RebrAIn’s Precision Targeting Solutions for Parkinson’s Disease
We are delighted to share that MedTech Strategist has featured RebrAIn in their latest issue.The article explores how our supervised AI-driven platform, OptimMRI, simplifies precision targeting for Deep Brain Stimulation (DBS) in Parkinson’s Disease. By enhancing...
User’s manual
Last release
OptimMRI US
OptimDBS EU
- CUG_OptimDBS-IT-Rev_4.pdf (Revision #4 | Revision date: 2024-06 | Lang.: IT)
- CUG_OptimDBS-EN-Rev_4.pdf (Revision #4 | Revision date: 2024-06 | Lang.: EN)
- CUG_OptimDBS-ES-Rev_4.pdf (Revision #4| Revision date: 2024-06 | Lang.: ES)
- CUG_OptimDBS-FR-Rev_4.pdf (Revision #4 | Revision date: 2024-06 | Lang.: FR)
Information notice
All revisions of the instructions manual are available for download below, in English and other languages. This manual details how to retreive and use the marked MRIs for surgery planning. Marked MRIs (3D DICOM) contain the targets as predicted by OptimDBS, a standalone tool developed by RebrAIn.
The use of those marked MRIs processed by OptimDBS is restricted to clinicians planning neurosurgery for patients with either Parkinson’s disease or essential tremor, by targeting the subthalamic nucleus (STN) or the ventral intermediate nucleus of the thalamus (VIM).
Carefully reading this instructions manual before use is strongly advised.
Any type of inappropriate use is prohibited.
A hard copy of this instructions manual can be obtained within 5 working days with no extra charge by contacting Rebrain at the following email address: support@rebrain.eu.
RebrAIn provides its partners with an access to its secure medical data exchange platform at transfer.rebrain.eu. Please contact our team with the above email address or via this website’s contact form to request an account. The current version of the instructions manual is also available for download on the data exchange platform, through the help menu of a connected account.
The instructions manuals below are available in PDF format. Any standard PDF reader, such as Acrobat Reader or Okular, is necessary
Sont disponibles dans la liste ci-dessous toutes les versions du manuel d’utilisation électronique en Français et dans d’autres langues. Ce manuel d’utilisation explique comment récupérer et utiliser lors la planification de la chirurgie les IRM marquées avec des cibles cérébrales prédites par OptimDBS, un logiciel autonome conçu par RebrAIn.
L’utilisation de ces images IRM (3D DICOM) marquées traitées avec OptimDBS est réservée au clinicien prévoyant d’effectuer une intervention neurochirurgicale pour le traitement de patient atteints de la maladie de Parkinson ou de Tremblements Essentiels en ciblant le noyau sous-thalamique, STN, ou le noyau ventral intermédiaire, VIM.
Il est recommandé de lire attentivement ce manuel d’instructions avant utilisation.
Toute utilisation inappropriée est interdite.
Une copie imprimée des instructions d’utilisation peut être obtenue dans les 5 jours ouvrés sans frais supplémentaires en contactant RebrAIn à l’adresse email suivante : support@rebrain.eu.
RebrAIn offre à ses collaborateur un accès à son service sécurisé d’échange de données médicales à transfer.rebrain.eu. Vous pouvez contacter l’équipe via le formulaire de contact pour faire la demande d’un compte. La version courante du manuel d’utilisation électronique est également accessible depuis le menu « Aide » sur la plateforme transfer.rebrain.eu une fois connecté à celle-ci.
Ces instructions d’utilisation sont fournies en format « PDF ». Un logiciel approprié, tel que Adobe Acrobat Reader, est requis pour les lire.
Archives
- CUG_OptimDBS-IT-Rev_3.pdf (Revision #3 | Revision date: 2022-06 | Lang.: IT)
- CUG_OptimDBS-EN-Rev_3.pdf (Revision #3 | Revision date: 2022-06 | Lang.: EN)
- CUG_OptimDBS-ES-Rev_3.pdf (Revision #3 | Revision date: 2022-06 | Lang.: ES)
- CUG_OptimDBS-FR-Rev_3.pdf (Revision #3 | Revision date: 2022-06 | Lang.: FR)
- CUG_OptimDBS EN Rev.2.pdf (Revision #2 | Revision date: 2021-10 | Lang.: EN)
- CUG_OptimDBS FR Rev.2.pdf (Revision #2 | Revision date: 2021-10 | Lang.: FR)
Publications
White Paper
OptimMRI from RebrAIn
A personalized, participative, preventive, predictive and evidence-based neurosurgical targeting service for patients with movement disorders caused by Parkinson’s Disease or Essential Tremor.
To receive our complete white paper on OptimMRI, please submit your request via the form below. Your details will help us verify eligibility and ensure the information is sent to the right audience.
